Description
ACP-0052, also known as SL-052 and ACP-SL-052, is a hypocrellin-based photosensitizer potentially for the treatment of prostate cancer.
Uses
SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT). SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP)-based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations.
References
[1] Antitumor Efficacy of Photodynamic Therapy Using Novel Nanoformulations of Hypocrellin Photosensitizer SL052
